US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
ScienceAlert on MSN
This week in science: Reversing Alzheimer's, solving a tapestry mystery, and more!
A promising Alzheimer's breakthrough as an experimental drug completely reverses mental decline in mice with advanced disease ...
Morning Overview on MSN
Scientists repair Alzheimer’s damage in mice instead of just slowing it
For decades, Alzheimer’s disease has been framed as a one‑way slide, with treatments aiming only to slow the descent. Now a ...
FAMILIES of teens who have fallen prey to ketamine have told of the horror of watching their kids turn into “zombies” in ...
Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ — Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback